Fulvestrant: all 236 studies that test it
Page 1 of 3. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.
- Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingNCT07892274Phase 3
- A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast CancerNot yet recruitingNCT07867262Phase 1
- Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerNot yet recruitingNCT07857226Phase 2
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingNCT07748208Phase 2
- A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.Not yet recruitingNCT07619066Phase 2
- A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingNCT07618390Phase 2
- Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingNCT07604272Phase 1
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsRecruitingNCT07540572Phase 1
- A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast CancerNot yet recruitingNCT07393321Phase 3
- A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast CancerRecruitingNCT07389733Phase 1/2
- To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerRecruitingNCT07368998Phase 2
- A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT07235618Phase 2
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingNCT07163481Phase 1
- Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsRecruitingNCT06993844Phase 1/2
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingNCT06979596Phase 2
- A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNot yet recruitingNCT06941142Phase 1
- A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerRecruitingNCT06856200Not applicable
- Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerNot yet recruitingNCT06849947Phase 2
- A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingNCT06788197Phase 1/2
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingNCT06757634Phase 3
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruitingNCT06726148Phase 1/2
- Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsRecruitingNCT06663072Phase 1
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3
- A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast CancerRecruitingNCT06172322Phase 1
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
- I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast CancersNot yet recruitingNCT05986071Phase 1/2
- Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyNot yet recruitingNCT05806671Phase 2
- A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.Not yet recruitingNCT05792410Phase 1/2
- VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingNCT05608252Phase 1/2
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingNCT05601440Phase 2
- Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Not yet recruitingNCT05577923Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
- Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorRecruitingNCT05536128Phase 2
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingNCT05524584Phase 2
- Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementRecruitingNCT05362760Phase 4
- Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02RecruitingNCT05205200Phase 2
- An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast CancerRecruitingNCT05186545Phase 2
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT05113368Phase 2
- The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast CancerRecruitingNCT05075512Phase 2
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingNCT04985266Phase 2
- Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR MutationRecruitingNCT04936295Phase 2
- Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast CancerNot yet recruitingNCT04337658Phase 3
- Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerRecruitingNCT04263298Phase 3
- Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesRecruitingNCT04092673Phase 1/2
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingNCT02476786Phase 2
- Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine TreatmentCompletedNCT05631795Phase 4Results posted
- Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast CancerCompletedNCT05101564Phase 2Results posted
- Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTerminatedNCT05082025Phase 2Results posted
- A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor CancerCompletedNCT05054374Phase 1/2Results posted
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Phase 3Results posted
- Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With FulvestrantTerminatedNCT04862143Phase 2Results posted
- Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)TerminatedNCT04738292Phase 2Results posted
- A Study of Abemaciclib in Indian Women With Advanced Breast CancerCompletedNCT04707196Phase 4Results posted
- Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast CancerTerminatedNCT04305236Phase 2Results posted
- Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT StudyTerminatedNCT04256941Phase 2Results posted
- Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantCompletedNCT04224272Phase 2Results posted
- A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerTerminatedNCT04031885Phase 4Results posted
- A Study of TAS-120 in Patients With Metastatic Breast CancerTerminatedNCT04024436Phase 2Results posted
- Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerActive, not recruitingNCT03939897Phase 1Results posted
- MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast CancerCompletedNCT03767335Phase 1Results posted
- Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial CancerCompletedNCT03643510Phase 2Results posted
- Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerCompletedNCT03633331Phase 2Results posted
- Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursCompletedNCT03620643Phase 2Results posted
- Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminatedNCT03439046Phase 3Results posted
- A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast CancerCompletedNCT03344536Phase 1/2Results posted
- Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast CancerTerminatedNCT03289039Phase 2Results posted
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT03280563Phase 1/2Results posted
- Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerCompletedNCT03238196Phase 1Results posted
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior TreatmentsCompletedNCT03056755Phase 2Results posted
- GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast CancerTerminatedNCT02983604Phase 1/2Results posted
- Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast CancerCompletedNCT02953860Phase 2Results posted
- Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.TerminatedNCT02936206Phase 1Results posted
- Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus PalbociclibCompletedNCT02913430Early Phase 1Results posted
- Estrogen Receptor Antagonist in Patients With Pulmonary Arterial HypertensionCompletedNCT02911844Phase 2Results posted
- Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerCompletedNCT02860000Phase 2Results posted
- A Study of Abemaciclib (LY2835219) in Participants With Breast CancerActive, not recruitingNCT02763566Phase 3Results posted
- A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast CancerCompletedNCT02675231Phase 2Results posted
- Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose PhaseCompletedNCT02640755Phase 1Results posted
- A Pre-Surgical PK Study of IM and Intraductally Delivered FulvestrantTerminatedNCT02540330Phase 2Results posted
- Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast CancerCompletedNCT02536742Phase 2Results posted
- Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast CancerCompletedNCT02491983Phase 2Results posted
- A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerCompletedNCT02447328Phase 4Results posted
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast CancerCompletedNCT02392611Phase 1Results posted
- A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast CancerCompletedNCT02384239Phase 2Results posted
- Endocrine Response in Women With Invasive Lobular Breast CancerCompletedNCT02206984Phase 2Results posted
- Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerCompletedNCT02049957Phase 2Results posted
- Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCompletedNCT02028507Phase 3Results posted
- Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerCompletedNCT01670877Phase 2Results posted
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.CompletedNCT01602380Phase 3Results posted
- AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast CancerCompletedNCT01597388Phase 1Results posted
- Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer WomenCompletedNCT01300351Phase 3Results posted
- Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer PatientsCompletedNCT01202591Phase 1/2Results posted
- Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal WomenCompletedNCT01186796Phase 1Results posted
- Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung CancerTerminatedNCT00932152Phase 2Results posted
- Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.CompletedNCT00921115Phase 2Results posted
- Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast CancerCompletedNCT00871858Phase 2Results posted
- Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor TherapyTerminatedNCT00722072Phase 2Results posted
- Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial CancerCompletedNCT00617188Phase 2Results posted